Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Introduction Data on real-world experiences for patients treated with ixekizumab is currently limited. Objectives Describe characteristics of ixekizumab-treated psoriasis patients and provide evidence of clinical outcomes using disease severity scores Body Surface Area (BSA) and Psoriasis Area and S...

Full description

Bibliographic Details
Main Authors: Wayne Gulliver, Michelle Penney, Rebecca Power, Susanne Gulliver, Sonia Montmayeur, Russel Burge
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
real-world effectiveness
ixekizumab
rapid clearance
Online Access:http://dx.doi.org/10.1080/09546634.2020.1755009

Internet

http://dx.doi.org/10.1080/09546634.2020.1755009

Similar Items